Argenica Therapeutics Share Price and Company Fundamentals
Last traded: Last Monday at 11:15 PM
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
Key Metrics
PE ratio
-
PB ratio
5.25
Dividend yield
0.00%
Beta
-
Market cap
-
Enterprise value
-
Company profile
| Primary activities | Development and commercialisation of a novel therapeutic |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | https://argenica.com.au |
| Mailing address | 117 Broadway Unit 4 Nedlands WA 6009 Australia |
| Phone / Fax | 61 8 9329 3396 / |
| Share registry | LINK MARKET SERVICES LIMITED |
Dividends
More: Argenica Therapeutics Dividend history, yield and payout ratio
Dividend yield
0.00%
Dividend amount
$0.00
Payout ratio
0.00%
Argenica Therapeutics paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AGN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
AGN's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of Mar 2023, following are the company executives and directors listed on Argenica Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | CEO, MD & Director | 250.25k | |
| Dr. Samantha South GAICD, MBA, Ph.D. | COO & Exec. Director | 198k | |
| Ms. Emma Waldon | CFO & Company Sec. | 46 | |
| Prof. Bruno Philip Meloni | Chief Scientific Officer | ||
| Dr. Meghan Thomas | Head of Clinical Devel. |
Profitability and management effectiveness
Profit margin
-282.83%
Operating margin
-284.33%
Return on assets
-35.82%
Return on equity
-63.45%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Argenica Therapeutics is and its enterprise value is .
Companies similar to Argenica Therapeutics (AGN)
Argenica Therapeutics (ASX:AGN) Frequently Asked Questions
1. What is Argenica Therapeutics's Stock Symbol?
Argenica Therapeutics trades on ASX under the ticker symbol "AGN".
2. What is Argenica Therapeutics's stock price today?
One share of AGN stock can currently be purchased for approximately $0.42.
3. How can I contact Argenica Therapeutics?
Argenica Therapeutics's mailing address is 117 Broadway Unit 4 Nedlands WA 6009 Australia. The company can be reached via phone at 61 8 9329 3396.
4. What is Argenica Therapeutics's official website?
The official website of Argenica Therapeutics is https://argenica.com.au.
5. Which share registry manages Argenica Therapeutics's stock?
Argenica Therapeutics's stock is managed by LINK MARKET SERVICES LIMITED.